Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression

Journal of Immunology

Volumn 163, Issue 11, 1999, Pages 6292-6300

  Lee, Kang Hun ^a   Wang, Ena ^b   Nielsen, Mai Britt ^b   Wunderlich, John ^b   Migueles, Steven ^c   Connors, Mark ^c   Steinberg, Seth M ^b   Rosenberg, Steven A ^b   Marincola, Francesco M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MELANOMA VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SPECIFICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MELANOMA; PRIORITY JOURNAL; PROLYMPHOCYTE; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; VACCINATION;

EID: 0033485764     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
2. Rosenberg, S. A., J. C. Yang, D. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, E. Dufour, L. Schwartzberg, P. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
3. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:37.
4. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
5. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J. Immunol. 157:2539.
6. Pass, H. A., S. L. Schwarz, J. R. Wunderlich, and S. A. Rosenberg. 1998. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4:316.
7. Altman, J. D., P. H. Moss, P. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
8. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103.
9. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395.
10. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827.
11. Bunce, M., C. M. O'Neill, M. C. Barnardo, P. Krausa, M. J. Browning, P. J. Morris, and K. I. Welsh. 1995. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355.
12. Krausa, P., M. Brywka, D. Savage, K. M. Hui, M. Bunce, J. L. Ngai, D. L. Teo, Y. W. Ong, D. Barouch, C. E. Allsop, et al. 1995. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45:223.
13. Topalian, S. L., D. Solomon, and S. A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142 :3714.
14. Wolfel, T., E. Klehmann, C. Muller, K. H. Schutt, K. H. Meyer zum Buschenfelde, and A. Knuth. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med 170:797.
15. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
16. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267.
17. Old, L. J., and Y. T. Chen. 1998. New paths in human cancer serology. J. Exp. Med. 187:1163.
18. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, et al. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:341.
19. Scheibenbogen, C., K. H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H. G. Rammensee, and U. Keilholz. 1997. Analysis of the T cell response to tumor and viral peptide antigens by an IFN-γ-ELISPOT assay. Int. J Cancer 71:932.
20. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16:201.
21. Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373.
22. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162:1780.
23. + T cells with soluble HLA-A2/Tax 11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J. Immunol. 162:1765.
24. Ogg, G. S., D. P. Rod, P. Romero, J. L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188:1203.
25. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
26. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677.
27. Lauritzsen, G. F., P. O. Hofgaard, K. Schenck, and B. Bogen. 1998. Clonal deletion of thymocytes as a tumor escape mechanism. Int. J. Cancer 78:216.
28. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination: functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911.
29. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243.
30. Moskophidis, D., F. Lechner, H. P. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758.
31. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.
32. Toes, R. E., S. P. Schoenberger, E. I. van der Voort, W. M. Kast, R. C. Hoeben, C. J. Melief, and R. Offringa. 1997. Activation or frustration of anti-tumor responses by T-cell-based immune modulation. Semin. Immunol. 9:323.
33. Effros, R. B., and G. Pawelec. 1997. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol. Today 18:450.
34. + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10:F17.
35. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855.
36. Zea, A. H., B. D. Curti, D. L. Longo, W. G. Alvord, S. L. Strobl, H. Mizoguchi, S. P. Creekmore, J. J. O'Shea, G. C. Powers, W. J. Urba, and A. C. Ochoa. 1995. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1:1327.
37. Wojtowicz-Praga, S. 1997. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20:165.
38. Matzinger, P. 1998. An innate sense of danger. Semin. Immunol. 10:399.